Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 820 results for "eli lilly"

Lilly must divest Sentinel products after FTC nod on Novartis deal
Reuters India

Lilly must divest Sentinel products after FTC nod on Novartis ...

(Adds details on divestiture, background on deal, share price) By Diane Bartz WASHINGTON, Dec 22 (Reuters) - Eli Lilly and Co has won approval to buy Novartis AG's animal health unit on condition that it divests its Sentinel line of products ... Yahoo! Finance, 10 hours ago

128 images for eli lilly

Ticker Report, 42 minutes ago
BioSpace, 11 hours ago
American Banking News, 6 days ago, 10 hours ago
Mubasher, 1 day ago
Jutia Group, 5 hours ago
Mubasher, 5 days ago
Pharma Letter, 9 hours ago
Jutia Group, 5 days ago, 1 week ago
Jutia Group

Company Update: Eli Lilly & Company (NYSE:LLY) Lilly Announces Diabetes Research Partnership with University of Surrey

[PR Newswire] INDIANAPOLIS, Dec. 22, 2014 /PRNewswire/ — Eli Lilly and Company (LLY) today announced a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type ...
 Jutia Group5 hours ago Lilly's Cyramza Receives Third FDA Approval  PharmaAsia10 hours ago Eli Lilly : Lilly Announces Diabetes Research Partnership with University of Surrey  4 Traders12 hours ago Lilly Announces Diabetes Research Partnership with University of Surrey  Canada NewsWire12 hours ago

Next Support Level for Eli Lilly (LLY) is $70.80

Eli Lilly (NYSE:LLY) has opened bearishly below the pivot of $72.13 today and has reached the first level of support at $71.60. Investors may be interested in a cross of the next downside pivot targets of $70.80
 Individual.com11 hours ago Next Resistance Level for Eli Lilly (LLY) is $71.54  Individual.com4 days ago

Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog

Eli Lilly and Company (LLY) and Adocia announced that they have entered into a worldwide licensing agreement for the development of an ultra-rapid insulin, BioChaperone Lispro, for the treatment of patients suffering from type I and type II ...
 Yahoo! Finance7 hours ago

Eli Lilly to sell heartworm line for Novartis deal approval

Eli Lilly will sell its heartworm treatment for dogs to garner U.S. approval for its $5.4 billion acquisition of the animal health division belonging to Norvartis. The Federal Trade Commission said
 Yahoo! UK and Ireland8 hours ago

Lilly jettisons Sentinel line as a condition for clearance of Novartis deal

The Federal Trade Commission approves Eli Lilly's (LLY -1.7%) acquisition of Novartis' (NVS +0.7%) animal health unit on the condition that it divest the latter's Sentinel line of products for treating heartworm in dogs. The FTC required the sale ...
 Seeking Alpha10 hours ago FTC Puts Conditions On Lilly's Deal To Buy Novartis Animal Unit  FirstWord Pharma9 hours ago

Eli Lilly Shares Sinking Lower, Down 2.0...

Eli Lilly (NYSE:LLY), a company whose shares are moving quickly, is trading 2.0% lower to $70.95. The Dow Jones Industrial Average is now trading 0.4% higher to 17,876 and the S&P is trading fractionally lower to 2,070. Eli Lilly (NYSE:LLY) has ...
 Financial News Network online10 hours ago

LLY March 2015 Options Begin Trading

Investors in Eli Lilly & Co. (LLY) saw new options become available today, for the March 2015 expiration.. Related Stocks: Stock Market XML and JSON Data API provided by FinancialContent Services, Inc. Nasdaq quotes delayed at least 15 ...
 CEOWorld Magazine11 hours ago
Pharma Letter

Eli Lilly and Adocia Come to $570 Million Insulin Deal

Dividend Stock Advisor Try it NOW Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream. Product Features: Diversified model ...
 TheStreet.com3 days ago Lilly signs development deal for ultra-rapid insulin  Seeking Alpha3 days ago UPDATE: Lilly rekindles deal with Adocia to develop ultra rapid insulin19-12-2014  Pharma Letter2 days ago Lilly to co-develop ultra-rapid insulin BioChaperone Lispro in partnership with Adocia  BusinessWeek3 days ago

Potential Eli Lilly (LLY) Trade Has 2.75% Downside Protection

After closing Thursday at $72.45, Eli Lilly and Co ("LLY) presents an attractive opportunity to get a 2.90% return in just 63 days, which is an annualized return of 16.77% (for comparison purposes ...
 Individual.com3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less